Abstract 1680P
Background
Chronic pain is reported by > 50% of patients recovering from breast cancer (BC). Adverse life experiences (ALEs) are associated with decreased psychosocial functioning in BC survivors, but their effect on pain has not been thoroughly explored. Sense of coherence (SOC) is the disposition to feel that life is predictable and manageable. Sense of danger (SOD) reflects expectations of harm from a particular event.
Methods
We are conducting a prospective study to assess if ALEs increase chronic adverse effects in patients with localized BC and identify mediating mechanisms. Patients are recruited before starting (neo)adjuvant oncological treatment and assessed periodically by validated questionnaires, including ALEs, SOC, SOD from BC, FACT-COG, FACT-ES, and brief pain inventory. Blood samples for inflammatory biomarkers are stored. This sub-study tested if ALEs are associated with baseline pain, measured as a composite score of pain intensity and interference, and examined the mediating role of SOC and SOD.
Results
Of 126 participants, 97 provided data on ALEs. Median age was 49 (range 23-75). 53.6% were treated in the neoadjuvant setting. Chemotherapy was planned for 62.9%. More ALEs correlated with more pain (r =. 34, p <. 001). Educational level and planned chemotherapy correlated with less pain. Serial mediation analysis revealed that after controlling for these variables, ALEs were indirectly associated with more pain through lower SOC followed by higher SOD from BC, CIs = 0.001, 0.103. Together, the model explained 38% of the variance in patients’ pain, F (5, 82) = 9.92, p <. 001. Age, BMI, CRP levels, and neutrophils to lymphocytes ratio were not associated with pain scores or with other study variables. Having surgery (vs planned surgery) was not associated with pain scores.
Conclusions
Exposure to a higher number of ALEs was associated with higher baseline pain in early BC patients before oncological treatment, mediated by decreased SOC and higher SOD from BC. These results stress the importance of addressing past trauma, sense of coherence, and sense of danger from BC to improve physical adverse effects such as pain. Further study will explore the effect of ALE, SOC, and SOD on pain persistence after adjuvant therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1636P - Health-related quality of life outcomes of androgen receptor pathway inhibitors versus taxanes versus standard of care in metastatic castration-resistant prostate cancer: Results from the ProBio trial
Presenter: Renée Bultijnck
Session: Poster session 11
1637P - Efficacy of talazoparib and enzalutamide in mCRPC patients previously treated with androgen receptor pathway inhibitors (ARPI) or docetaxel: Post hoc analysis from both cohorts in TALAPRO-2 study
Presenter: Neeraj Agarwal
Session: Poster session 11
1638P - Enzalutamide (enza) with or without leuprolide in patients (pts) with high-risk biochemically recurrent (hrBCR) prostate cancer (PC): EMBARK post hoc analysis by age
Presenter: Neal Shore
Session: Poster session 11
1639P - Self efficacy in people with prostate cancer in the UK: A large, digital survey
Presenter: Joe O'Sullivan
Session: Poster session 11
1640P - Development and validation of a machine learning-based risk model for metastatic disease in nmCRPC patients
Presenter: Ziyun Wang
Session: Poster session 11
1641P - Phase I/II trial of oral masofaniten (EPI-7386) in combination with enzalutamide (Enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects
Presenter: Christos Kyriakopoulos
Session: Poster session 11
1642P - Integrated prognostic score in metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel: A CABASTY posthoc analysis
Presenter: Charles Vauchier
Session: Poster session 11
1643P - Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC)
Presenter: Bicky Thapa
Session: Poster session 11
1644P - PSA trajectories and prediction of time to no-longer clinically benefitting in metastatic castration-resistant prostate cancer: Insights from the ProBio trial
Presenter: Lana Broer
Session: Poster session 11
1645P - Tumour suppressor gene signature predicts early progression in metastatic hormone-sensitive metastatic prostate cancer (mHSPC) patients
Presenter: Marta Garcia De Herreros
Session: Poster session 11